<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00969332</url>
  </required_header>
  <id_info>
    <org_study_id>09-02-079-02</org_study_id>
    <nct_id>NCT00969332</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study to Determine if Giving Intravenous Fish Oil Helps Children With Liver Disease</brief_title>
  <acronym>FO</acronym>
  <official_title>Omegaven and Parenteral Nutrition Associated Cholestasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate if intravenous fish oil, commercially available as
      Omegaven, safely and effectively reverses parenteral nutrition associated cholestasis in
      children.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infants dependent on parenteral nutrition for greater than 1 year who develop parenteral
      nutrition associated cholestasis will universally face mortality unless they receive a timely
      liver and/or small bowel transplant. Although transplant survival has improved in recent
      years, survival is not guaranteed, and transplant care remains costly. Alternative
      nutritional and pharmacological strategies are imperative to improve the clinical outcomes of
      infants with intestinal failure and parenteral nutrition associated cholestasis. In both
      animal and human studies, intravenous fish oil, a lipid emulsion rich in omega-3 fatty acids
      and Vitamin E, and lacking phytosterols, has been shown to ameliorate parenteral nutrition
      associated cholestasis and improve morbidity and mortality. The purpose of this pilot study
      is to investigate if Omegaven, a commercially available intravenous fish oil, at 1 g/kg/d,
      will safely reverse liver disease in 80 subjects with parenteral nutrition associated
      cholestasis. Subjects can initially receive a maximum of 6 months (24 weeks) of intravenous
      fish oil. If the subject re-develops liver disease and still satisfies inclusion/exclusion
      criteria, the intervention can be restarted. Study subjects will be compared to a historical
      cohort of children with Short Bowel Syndrome and parenteral nutrition associated cholestasis
      who have been receiving standard intravenous soybean oil for &gt; 60 days. The fish oil cohort
      will be followed for a total of 5 years to determine if transplant-free mortality is reduced.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study intervention was approved by the FDA
  </why_stopped>
  <start_date type="Actual">August 2009</start_date>
  <completion_date type="Actual">February 12, 2019</completion_date>
  <primary_completion_date type="Actual">January 12, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Reversal of Parenteral Nutrition Associated Cholestasis</measure>
    <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>24 weeks, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>expiration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Underwent a Transplant</measure>
    <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>includes isolated liver or multi-visceral transplant including liver graft</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Full Enteral Feeds</measure>
    <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>discontinuation of parenteral nutrition</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth Z-scores</measure>
    <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>Weight Z-scores at the end of the study. Formula used: (weight at end of study-average weight of reference population)/standard deviation of weight of reference population.
The Z-score indicates the number of standard deviations away from the mean. A weight Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A weight Z-score &lt;/= -2 indicates an underweight or malnourished status, while a weight Z-score &gt;/= 2 indicates an overweight or obese status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Counts at the End of the Study - Risk of Bleeding</measure>
    <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>platelet counts at the end of the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Essential Fatty Acid Deficiency</measure>
    <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>triene:tetraene ratio less than 0.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Inflammation</measure>
    <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>Serum Cytokines - interleukin-8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Sterol Metabolism</measure>
    <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>Serum Phytosterols - stigmasterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Bile Acid Metabolism</measure>
    <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>Serum Bile acids - total chenodeoxycholic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of Fatty Acid Metabolism</measure>
    <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
    <description>Erythrocyte fatty acid - Docosahexaenoic Acid</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Cholestasis</condition>
  <arm_group>
    <arm_group_label>Omegaven</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omegaven</intervention_name>
    <description>0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday</description>
    <arm_group_label>Omegaven</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical evidence of parenteral nutrition associated cholestasis

          -  Direct bilirubin greater or equal to 2 mg/dL on 2 consecutive measurements

          -  Expected parenteral nutrition course greater than 30 days

          -  Acquired or congenital gastrointestinal disease

          -  &gt; 2 weeks of age and &lt; 18 years of age

          -  &gt; 60% calories from parenteral nutrition

          -  Failed standard therapies to prevent progression of liver disease (Actigal, cyclic
             parenteral nutrition, avoidance of overfeeding, reduction/removal of copper from
             parenteral nutrition if elevated my laboratory analysis, advancement of enteral feeds)

        Exclusion Criteria:

          -  Inborn errors of metabolism

          -  Extracorporeal Membrane Oxygenation

          -  Seafood, egg, or Omegaven allergy

          -  Documented case of liver disease other than Parenteral Nutrition Associated
             Cholestasis

          -  Hemorrhagic disorder

          -  Anticoagulant therapy

          -  Hemodynamically unstable or in shock

          -  Comatose state

          -  Stroke, pulmonary embolism, recent myocardial infarction

          -  Diabetes

          -  Fatal chromosomal disorder

          -  Enrollment in any other clinical trial involving an investigational agent

          -  Patient, parent, or legal guardians unable or unwilling to give consent

          -  Patient expected to be weaned from parenteral nutrition in 30 days

          -  unable to tolerate necessary monitoring

          -  Patient requiring aspirin or toradel or motrin

          -  Patient requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kara L Calkins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Calkins KL, Dunn JC, Shew SB, Reyen L, Farmer DG, Devaskar SU, Venick RS. Pediatric intestinal failure-associated liver disease is reversed with 6 months of intravenous fish oil. JPEN J Parenter Enteral Nutr. 2014 Aug;38(6):682-92. doi: 10.1177/0148607113495416. Epub 2013 Jul 26.</citation>
    <PMID>23894176</PMID>
  </results_reference>
  <results_reference>
    <citation>Calkins KL, DeBarber A, Steiner RD, Flores MJ, Grogan TR, Henning SM, Reyen L, Venick RS. Intravenous Fish Oil and Pediatric Intestinal Failure-Associated Liver Disease: Changes in Plasma Phytosterols, Cytokines, and Bile Acids and Erythrocyte Fatty Acids. JPEN J Parenter Enteral Nutr. 2018 Mar;42(3):633-641. doi: 10.1177/0148607117709196. Epub 2017 Dec 18.</citation>
    <PMID>28521607</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang C, Venick RS, Shew SB, Dunn JCY, Reyen L, Gou R, Calkins KL. Long-Term Outcomes in Children With Intestinal Failure-Associated Liver Disease Treated With 6 Months of Intravenous Fish Oil Followed by Resumption of Intravenous Soybean Oil. JPEN J Parenter Enteral Nutr. 2019 Aug;43(6):708-716. doi: 10.1002/jpen.1463. Epub 2018 Nov 8.</citation>
    <PMID>30411372</PMID>
  </results_reference>
  <results_reference>
    <citation>Ong ML, Venick RS, Shew SB, Dunn JCY, Reyen L, Grogan T, Calkins KL. Intravenous Fish Oil and Serum Fatty Acid Profiles in Pediatric Patients With Intestinal Failure-Associated Liver Disease. JPEN J Parenter Enteral Nutr. 2019 Aug;43(6):717-725. doi: 10.1002/jpen.1532. Epub 2019 Mar 22.</citation>
    <PMID>30900274</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 31, 2009</study_first_submitted>
  <study_first_submitted_qc>August 31, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2009</study_first_posted>
  <results_first_submitted>July 1, 2019</results_first_submitted>
  <results_first_submitted_qc>January 31, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Kara L. Calkins, MD</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>liver</keyword>
  <keyword>parenteral nutrition</keyword>
  <keyword>fish oil</keyword>
  <keyword>omegaven</keyword>
  <keyword>children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholestasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT00969332/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for this study began in May 2005. Patients were recruited from the inpatient and outpatient setting at the University of California, Los Angeles.</recruitment_details>
      <pre_assignment_details>There was no wash-out or run-in period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Omegaven</title>
          <description>Omegaven, 0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>62 subjects were consented for the study. 3 subjects were withdrawn from the study prior to starting the intervention. Hence, 59 subjects started the intervention and baseline characteristics are provided for these 59 subjects.</population>
      <group_list>
        <group group_id="B1">
          <title>Omegaven</title>
          <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="59"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="707.9" spread="1366.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Reversal of Parenteral Nutrition Associated Cholestasis</title>
        <description>weeks</description>
        <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reversal of Parenteral Nutrition Associated Cholestasis</title>
          <description>weeks</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.1" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Death</title>
        <description>expiration</description>
        <time_frame>24 weeks, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Death</title>
          <description>expiration</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Underwent a Transplant</title>
        <description>includes isolated liver or multi-visceral transplant including liver graft</description>
        <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Underwent a Transplant</title>
          <description>includes isolated liver or multi-visceral transplant including liver graft</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Full Enteral Feeds</title>
        <description>discontinuation of parenteral nutrition</description>
        <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Full Enteral Feeds</title>
          <description>discontinuation of parenteral nutrition</description>
          <units>weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.49" spread="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Growth Z-scores</title>
        <description>Weight Z-scores at the end of the study. Formula used: (weight at end of study-average weight of reference population)/standard deviation of weight of reference population.
The Z-score indicates the number of standard deviations away from the mean. A weight Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A weight Z-score &lt;/= -2 indicates an underweight or malnourished status, while a weight Z-score &gt;/= 2 indicates an overweight or obese status.</description>
        <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Growth Z-scores</title>
          <description>Weight Z-scores at the end of the study. Formula used: (weight at end of study-average weight of reference population)/standard deviation of weight of reference population.
The Z-score indicates the number of standard deviations away from the mean. A weight Z-score of 0 is equal to the mean with negative numbers indicating values lower than the mean and positive values higher. A weight Z-score &lt;/= -2 indicates an underweight or malnourished status, while a weight Z-score &gt;/= 2 indicates an overweight or obese status.</description>
          <units>Z-score</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Counts at the End of the Study - Risk of Bleeding</title>
        <description>platelet counts at the end of the study</description>
        <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Counts at the End of the Study - Risk of Bleeding</title>
          <description>platelet counts at the end of the study</description>
          <units>x10^3 cells/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220.9" spread="134.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Essential Fatty Acid Deficiency</title>
        <description>triene:tetraene ratio less than 0.2</description>
        <time_frame>24 weeks, death, transplant, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Essential Fatty Acid Deficiency</title>
          <description>triene:tetraene ratio less than 0.2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Inflammation</title>
        <description>Serum Cytokines - interleukin-8</description>
        <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Inflammation</title>
          <description>Serum Cytokines - interleukin-8</description>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Sterol Metabolism</title>
        <description>Serum Phytosterols - stigmasterol</description>
        <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Sterol Metabolism</title>
          <description>Serum Phytosterols - stigmasterol</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Bile Acid Metabolism</title>
        <description>Serum Bile acids - total chenodeoxycholic acid</description>
        <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Bile Acid Metabolism</title>
          <description>Serum Bile acids - total chenodeoxycholic acid</description>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Markers of Fatty Acid Metabolism</title>
        <description>Erythrocyte fatty acid - Docosahexaenoic Acid</description>
        <time_frame>24 weeks, death, or discontinuation of Parenteral Nutrition (whichever comes first)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Omegaven</title>
            <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 g/kg/d intravenous every day for 2 days, then 1 g/kg/d intravenous everyday</description>
          </group>
        </group_list>
        <measure>
          <title>Markers of Fatty Acid Metabolism</title>
          <description>Erythrocyte fatty acid - Docosahexaenoic Acid</description>
          <units>Percent of Sum of Fatty Acids</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Omegaven</title>
          <description>0.5 g/kg/d IV x 2 days, then 1 g/kg/d IV for 24 weeks or until parenteral nutrition discontinuation, death or transplant, whichever comes first. Subjects are eligible to restart Omegaven should they re-satisfy inclusion/exclusion criteria.
Omegaven: 0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Platelet count less than 20,000K</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Bleeding requiring product replacement or medical intervention (does not include pressure or specific medications) or surgical intervention.</description>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Hypotension requiring pressor support.</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotizing Enterocolitis</sub_title>
                <description>necrotizing enterocolitis (stage II or III).</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <description>Bacteremia, Urosepsis, Fungemia, Viral sepsis - positive culture with symptoms and need for more than 5 days of antibiotics/antifungals</description>
                <counts group_id="E1" events="39" subjects_affected="25" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <description>Diagnosis by clinical team</description>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Diagnosis by clinical team and positive urine culture and need for at least 5 days of antibiotics</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizures</sub_title>
                <description>EEG or clinical diagnosis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <description>Requiring need for dialysis.</description>
                <counts group_id="E1" events="31" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <description>Change in respiratory status requiring intubation</description>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <description>Platelet count &lt;100,000 cell/cu.mm</description>
                <counts group_id="E1" events="148" subjects_affected="28" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <description>Platelet count &gt;500,000 cu.mm</description>
                <counts group_id="E1" events="28" subjects_affected="15" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <description>White blood cell count &lt;5000 cells/cu.mm</description>
                <counts group_id="E1" events="106" subjects_affected="23" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Increased International Normalized Ratio</sub_title>
                <description>International Normalized Ratio &gt;1.4</description>
                <counts group_id="E1" events="106" subjects_affected="21" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Clinical Bleeding</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <description>Change in blood pressure requiring the use of pressor support</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Serum glucose &lt; 60 mg/dL</description>
                <counts group_id="E1" events="247" subjects_affected="39" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Serum glucose &gt;200 mg/dL</description>
                <counts group_id="E1" events="73" subjects_affected="24" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bowel Rejection</sub_title>
                <description>Clinical and histological evidence of rejection as well as clinical diagnosis by medical team</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <description>Serum sodium less than 130</description>
                <counts group_id="E1" events="37" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <description>Triglycerides more than 300 mg/dL</description>
                <counts group_id="E1" events="7" subjects_affected="3" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <description>potential of hydrogen less than 7.2 and/or requiring medical intervention (volume support, sodium bicarbonate)</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Acute Life Threatening Event</sub_title>
                <description>Diagnosis by clinical team</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Creatinine</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <description>Change in respiratory status requiring intubation or other support.</description>
                <counts group_id="E1" events="19" subjects_affected="14" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>early termination because intervention was FDA approved, single site study, prospective observational study, small sample size, change in clinical practice over time</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Kara L. Calkins</name_or_title>
      <organization>UCLA</organization>
      <phone>310-825-9330</phone>
      <email>KCalkins@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

